Boston Scientific announced a definitive agreement to acquire Penumbra for about $14.5 billion, combining Boston Scientific’s cardiovascular platform with Penumbra’s thrombectomy and embolization technologies. The cash-and-stock transaction values Penumbra at roughly 19% above its prior share price and aims to broaden Boston Scientific’s reach into fast-growing thrombectomy and embolization markets. The deal covers Penumbra’s catheter systems for clot removal in stroke, pulmonary embolism and peripheral thrombosis as well as embolization products. Boston Scientific said the acquisition complements recent medtech transactions and positions the company to enter new vascular segments; the purchase remains subject to shareholder approval and customary closing conditions and is expected to close in 2026. Analysts noted the acquisition follows sector consolidation after Stryker’s recent thrombectomy buy and reflects continued appetite among larger device makers to secure growth assets in interventional vascular care.